In this study we have characterized the effects of cysteamine (CHS) on the cellular content and release of immunoreactive somatostatin (S-14 LI), insulin (IRI), and glucagon (IRG) from monolayer cultures of neonatal rat islets. Incubation of cultures with 0.1-10 mM CHS for 1 h led to an apparent, dosedependent reduction of cellular S-14 LI that was 50% of control at 0.3 mM, 87% at 1 mM, and 95% at 10 mM. IRI content was unaffected by CHS up to 1 mM, but at 10 mM 90% loss of IRI occurred. All concentrations were without effect on IRG content. The loss of S-14 LI and IRI was completely reversible with time, but with different recovery rates for the two hormones (48 h for S-14 LI, and 72 h for IRI). Released S-14 LI rose progressively with increasing doses of CHS from 21±2.5 pg/ml per hour to 41±1.4 pg/ml per hour at CHS concentrations of 5 mM and 10 mM. IRI and IRG secretion were both also significantly enhanced (by 55% and 88%, respectively), despite the elevated medium S-14 LI. Since CHS reduced cellular S-14 LI but augmented medium S-14 LI, the relative effects of CHS (1 mM) and immunoneutralization with antibody to S-14 LI on IRI and IRG secretion were tested. Anti S-14 LI alone stimulated basal IRG (67%) but not IRI. Cultures rendered S-14 LI deficient with both CHS and anti-S-14 LI exhibited threefold and 23-fold potentiation of IRG and IRI secretions, respectively, greater than that expected from the separate effects of the two agents. Increasing medium glucose from 2.8 mM to 16.7 mM stimulated IRI release by 86% and suppressed IRG by 53%. CHS (1 mM) and anti-S-14 LI further augmented stimulated IRI release, by 30%; although 16.7 mM glucose suppression of IRG was still maintained under these conditions, the quantitative IRG response was significantly greater. These results suggest that CHS induces an apparent loss of islet S-14 LI, and at high doses, of IRI as well, but has no effect on A cells. 
Introduction
The sulfhydryl drug cysteamine (CHS)' or mercaptoethylamine was reported by Selye and Szabo (1) in 1973 to induce severe perforating duodenal ulcers in rats. The ulcerogenic effect of this agent was found to be due to an increase in gastric acid and gastrin secretion and could be prevented by somatostatin administration (2) . Subsequent studies by Szabo and Reichlin (3) showed that CHS produced an apparent depletion of somatostatin-14-like immunoreactivity (S-14 LI) in the gastric and duodenal mucosa and thereby induced peptic ulceration probably through abolition of the paracrine inhibitory effects of somatostatin on gastrin and gastric acid secretion. A number of laboratories have now confirmed that CHS administered orally or systemically in single doses evokes a rapid, generalized, and reversible loss of S-14 LI from tissues and plasma (3) (4) (5) (6) (7) (8) . Cysteamine does not lead to a true loss of somatostatin molecules; it probably acts through a chemical modification of the disulfide bond to mask the antigenic sites in the cyclized segment of S-14, a change that also renders the molecule biologically unreactive (4, 7, (9) (10) (11) . The biological effects resulting from cysteamine-induced S-14 LI loss can be reversed by exogenous S-14 administration (2, 7) .
Considerable indirect evidence suggests that the somatostatin producing D cells of the islets of Langerhans serve as important physiological regulators of A and B cell function (12) (13) (14) (15) (16) (17) (18) (19) . The effects of somatostatin on the A and B cells are believed to be mediated both through intra-islet regulatory interactions, as well as systemically from small concentrations of the peptide reaching the islet cells via the arterial circulation. Evidence for these concepts derives from such observations as the nonrandom distribution of D cells in relation to A and B cells in the islets (12) , the presence of gap junctions between adjacent islet cells ( 12) , the finding of specific receptors for somatostatin on B, A, and D cells in numbers that correlate closely with the known actions of the peptide on each of the three islet cell types (17) , and the demonstration that concentrations of somatostatin comparable to those in the arterial circulation can inhibit insulin and glucagon release (16) . Furthermore, electrophysiological studies (19) and the transfer of small molecules from one cell type to another (12) (13) (14) (15) 18 ) strongly suggest that intercellular communication is an important mechanism for islet cell regulation.
In the absence of a specific antagonist of somatostatin or a means for selective ablation of islet D cells, direct demonstration of a physiological role of somatostatin in the islet has proved difficult. Although antibody to somatostatin has been widely used as a tool for blocking the effects of released somatostatin, such immunoneutralization experiments with intact or isolated mammalian islets have yielded variable and contradictory results probably because of poor or uneven penetration of antibody molecules into the islet interstitial spaces (20-25). The availability of CHS, and especially its use combined with somatostatin antibody on monolayer cultures of islet cells, has afforded a potential means for inducing total islet somatostatin deficiency for investigating A and B cell function in a somatostatin-free environment. In this study we have characterized the in vitro effects of CHS, alone, and in combination with somatostatin antibody, on islet cell function. Specifically, we have (a) compared the effects of CHS on the cellular content and release of somatostatin, insulin, and glucagon; (b) determined the dose-response characteristics of CHS; (c) analysed the molecular forms of S-14 LI inactivated by CHS; (d) determined whether CHS exerts a selective action on D cells or whether A and B cells are also affected; (e) investigated the effects of CHS-induced islet somatostatin depletion on insulin and glucagon secretion; (f) compared the effects of somatostatin deficiency in cells (induced by CHS) and in medium (neutralized with excess somatostatin antibody), on insulin and glucagon secretion.
Methods
Monolayer cultures of islet cells. Monolayer cultures of pancreatic islet cells from 3-d-old Wistar rats were established in 35-mm diam plastic Petri dishes by minor modifications of the technique previously described from our laboratory (26) and used from day 8 to day 12. The culture medium consisted of Eagle's minimum essential medium with Earle's salt base supplemented with 10% heat-inactivated fetal calf serum (Gibco Laboratories, Long Island, NY), penicillin (100 U/ ml), streptomycin (100 gg/ml), and fungizone (0.25 Mg/ml). The glucose concentration in the medium was 16.7 mM until 24 h before the experiments, when it was decreased to 5.6 mM. For the immunocytochemical localization of somatostatin, insulin, and glucagon positive cells, the indirect immunofluorescence technique was used on islet cells fixed in situ (27) collected and centrifuged (500 g for 10 min) to remove desquamated cells, and the supernatant was stored at -20'C for subsequent assays.
The cells were scraped in 1 ml 1 N acetic acid at 0VC, the islet hormones were extracted by sonication and boiling (28) , the extract centrifuged (1,000 g for 10 min), and the supernatant was kept at -20'C for RIA. Neutralization experiments with anti-somatostatin antibody. Immunoneutralization of released somatostatin was accomplished by including in the incubation medium 10 Al/ml of a potent sheep antiserum against S-14 LI (binding capacity, 10 Ag S-14/ml) (29) , or an equivalent volume of normal sheep serum (NSS). This amount of antibody was calculated to be 1,000 times in excess of the quantity required to neutralize the basally released S-14 LI. The presence of excess antibody in the medium was confirmed for each experiment by reacting 0.1 ml of the antibody containing medium from each dish before and after exposure to the cultures with 5 pg ['25I-Tyr]-S-14 for 24 h at 4VC. Mean binding capacities of 81±1% (before) and 82±0.5% (after) were obtained.
RIAs. Somatostatin-like immunoreactivity in the medium and in cell extracts was measured as S-14 LI by RIA using rabbit antibody R149 (directed towards the central segment of S-14, which detects S-14 and somatostatin-28 [S-28] equally), ['251-Tyr]-S-14, and S-14 standards (28). Assay sensitivity was 0.7 pg S-14. Immunoreactive insulin (IRI) was measured by RIA using Wright guinea pig antiporcine insulin serum, '25l-porcine insulin, and rat insulin standards (Novo Industrie, Denmark) (26) . Assay sensitivity was 20 pg. Immunoreactive glucagon (IRG) was measured by RIA using rabbit antibody 30K (R. H. Unger, Dallas, TX), '25I-porcine glucagon, and porcine glucagon standards (Novo Industrie, Denmark) (26) . Assay sensitivity was 3 pg. The nonspecific effect of cysteamine on antibody binding of radioligand was excluded for each of the three RIAs by incubating medium containing 1.0 mM and 10 mM cysteamine in the RIAs. These concentrations of cysteamine were without effect on radioligand binding of antibody in each of the three assay systems. Likewise, cysteamine (10 mM) did not reduce the binding capacity of the sheep anti-S-14 LI serum when incubated with it in the immunoneutralization experiments.
Gel chromatography. The molecular forms of S-14 LI in cell extracts were characterized by gel chromatography (30) . A 70 X 1-cm column of Sephadex G-50 (superfine) was eluted with 6 M urea, 50 mM P04, pH 7.5. S-14 LI in the l-ml fractions was determined by RIA. The elution positions of S-14 and S-28 were determined by precalibration of the columns with 1-2 ng synthetic peptide eluted with 6 M urea, 50 mM P04, and measured as S-14 LI by RIA of the column filtrate.
Statistical analysis. Data were analysed by analysis of variance as applied to multifactorial experiments with unequal cell frequencies (31) . The unpaired Student's t test was used for comparing the recovery of S-14 LI and IRI between CHS and control cultures.
Results
Effect of CHS on cellular content ofsomatostatin, insulin, and glucagon. Fig. 1 shows the effect of increasing concentrations of CHS on islet hormone content. CHS induced a severe, dose-dependent depletion of islet S-14 LI, which was 50% of control at 0.3 mM, 87% at 1 mM, and 95% at 10 mM. The drug was without effect on islet IRI content up to a concentration of 1 mM. Higher concentrations led to a progressive loss of islet IRI content, which reached 11% of control values at 10 mM. All concentrations of CHS tested were without effect on islet IRG content. Islet S-14 LI depletion was completely reversible with time. In the experiment shown in Fig. 2 , cellular S-14 LI was determined daily for 4 To determine which molecular forms of S-14 LI were affected by CHS, extracts of control cultures or cultures exposed to CHS 1 mM for 1 h were subjected to Sephadex G-50 chromatography. 98% of S-14 LI in control cultures coeluted with synthetic S-14; the remaining 2% corresponding to a 14-kD prosomatostatin form (Fig. 3) . Residual S-14 LI in CHStreated cultures was also predominantly S-14, but the relative amount of prosomatostatin (9%) was much higher than in 15- Effect of CHS on basal release of somatostatin, insulin, and glucagon. Effect of CHS and somatostatin antibody on basal insulin and glucagon secretion. Since CHS depleted cellular S-14 LI content but increased medium S-14 LI, the next set of experiments (Fig. 5 ) was performed to compare the relative effects on basal insulin and glucagon release of either CHS alone or CHS + anti-S-14 LI serum to produce a deficiency of S-14 LI in both cells and in medium. Basal IRG secretion from the cultures increased by 67% from 0.6±0.05 ng/ml per hour to 1±0.1 ng/ml per hour (P < 0.05) in the presence of excess sheep anti-S-14 LI antibody compared with nonimmune sheep serum (NSS). 1 mM CHS also significantly enhanced basal IRG secretion as shown earlier (Fig. 1) to about the same extent (by 57%) as with S-14 LI antibody. Cultures rendered S-14 LI deficient with both CHS and antibody exhibited potentiation of IRG secretion from 0.6±0.05 ng/ml per hour to 1.75±0.26 ng/ml per hour, a response nearly three times greater (186% increase) than with either agent alone.
In the case of IRI secretion, CHS produced the expected increase in basal release (10.5±0.5 ng/ml per hour compared with 8.2±0.5 ng/ml per hour) (P < 0.05), whereas S-14 LI antibody was ineffective. The combined use of antibody and CHS evoked a marked 2.3-fold increase in IRI secretion to a level of 18.6±2 ng/ml per hour, much greater than that expected from the separate effects of these two agents.
Effect of glucose on insulin and glucagon secretion in the presence of CHS and somatostatin antibody. In this set of experiments the effect of glucose on B and A cell function in cultures exposed to 1 mM CHS or CHS and S-14 LI antibody was examined (Fig. 6 and Table I ). At a glucose concentration of 2.8 mM, IRI and IRG secretion were both stimulated by CHS and further stimulated by CHS and anti-S-14 LI. These findings are analogous to those obtained in Fig. 5 
Discussion
Since the first demonstration that CHS depletes 5-14 LI from tissues and plasma (3), there has been a steady proliferation of reports characterizing the detailed endocrine effects of this drug (4-11, 32, 33) . To date, only S-14 LI and prolactin have been reported to be susceptible to CHS out of a wide range of peptide and polypeptide hormones tested. Based on the present findings, IRI is also depleted by CHS but at doses at least ten times greater than those required for S-14 LI and prolactin (32) . The mechanism of action of CHS on somatostatin has not been completely elucidated. It has been suggested that CHS might act by accelerating the intracellular degradation of somatostatin, thereby inducing a true depletion of S-14 LI (3), S-14 LI in cultured islet cells, as in the whole rat pancreas, consists almost entirely of the S-14 molecular species. From our gel chromatographic analyses of S-14 LI in CHS-treated islet cells, it is evident that S-14 is the main molecular form inactivated by CHS. Since the cultures contained virtually no S-28 equivalent material, the effect of CHS on S-28 cannot be determined from this study. Our finding of a relative accumulation of prosomatostatin in CHS-exposed cultures (from 2% to 9% of total S-14 LI) is of interest and suggests increased synthesis and/or impaired post-translational enzymatic pro- (12) (13) (14) (15) (16) (17) (18) (19) . Such interactions could be mediated by a paracrine process (thought to occur when a substance secreted by a cell into the interstitial space influences the function of an adjacent cell), and/or through gap junctional coupling, allowing direct cell to cell communication. For example, the finding that intracellular S-14 LI depletion is accompanied by stimulation of IRI and IRG secretion even in the presence of elevated extracellular concentrations of S-14 LI (Fig. 4) reduction in basal IRG output was found). These differences are difficult to explain but perhaps can be accounted for by the very dissimilar model systems, as well as differences in the dose of CHS, route of administration, and the time interval after CHS before the experiments were performed. The use of immunoneutralization alone for assessing a functional role of endogenous somatostatin on insulin and glucagon secretion from mammalian islets has been described from several laboratories, with conflicting results (20-25, 34) . Passive immunization with anti-S-14 LI serum using whole animals or the isolated perfused pancreas has generally shown no direct effect on IRI or IRG secretion because of poor penetration of antibody molecules into intact islets (20) (21) (22) . Isolated islets exposed to anti-S-14 gamma globulin have been reported by Itoh et al. (25) to secrete increased quantities of IRI and IRG. Other studies, however, also using isolated islets or monolayer cultures of islets, have found no effect of anti-S-14 LI on IRI secretion (23) or on IRG secretion (34).
These reports highlight the inadequacies of the approaches used so far for elucidating direct local effects of somatostatin on A and B cells. As 
